Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Development of a Quadrivalent Combined DTaP-HepB Vaccine with a Low Toxicity and a Stable HBsAg Immunogenicity

  • Published : 2002.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

When developing a combined DTaP-HepB vaccine, toxicity and HBsAg immunogenicity are both important considerations. Thus, for a combined DTaP-HepB vaccine with a low toxicity, the effect of the DTaP content and $Al(OH)_3$, gel concentration on the vaccine toxicity was investigated. Within the range studied, the higher the concentrations, the higher the vaccine toxicity. The importance of the tetanus toxoid content in the combined DTaP-HepB vaccine was also revealed. A higher concentration of the tetanus toxoid was found to have a negative effect on the stability of the HBsAg immunogenicity in the combined vaccine. Accordingly, considering the factors affecting toxicity and HBsAg immunogenicity, a novel DTaP-HepB vaccine (30 Lf/ml of diphtheria toxoid, 5 Lf/ml of tetanus toxoid, 10 $\mu\textrm{g}$ PN/ml of acellular pertussis, 24 $\mu\textrm{g}$/ml of HBsAg, and 500 $\mu\textrm{g}$ Al/ml of $Al(OH)_3$ gel) was developed. It has a low toxicity and a stable HBsAg immunogenicity and also satisfies the potency criteria of K-FDA for a combined DTaP vaccine.

Keywords

References

  1. Vaccine v.26 Development and clinical application of new polyvalent combined pardiatric vaccines. Andre, F. E.
  2. Strategies in Vaccine Design The selective induction of different immune responses by vaccine adjiuvants Cooper, P. D.;Ada, G. L.(ed.)
  3. Biologicals Workshop on Standardisation of Aluminium Adsorbed Vaccines. Corbel, M. J.;E. Griffiths;R. Winsnes.
  4. Pediatr. Infect. Dis. J. v.19 Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Greenberg, D. P.;V. K. Wong;S. Partridge;S. J. Chang;J. Jing;B. J. Howe;J. I. Ward. https://doi.org/10.1097/00006454-200012000-00003
  5. Vaccine v.11 Adjuvants - a balance between toxicity and adjuvanticity. Gupta, R. K.;E. H. Relyveld;E. B. Lindbald;B. Bizzini;S. Benefraim;C. K. Gupta https://doi.org/10.1016/0264-410X(93)90190-9
  6. Vaccine Design: The Subunit and Adjuvant Approach. Adjuvant properties of aluminum and calcium compounds Gupta, R. K.;B. E. Rost;E. Relyveld;G. R. Siber.;Powell. M. F.(ed.)Newman, M. J.(ed.)
  7. Vaccines v.13 Adjuvants for human vaccine - current status, problems and future prospects. Gupta, R. K.;G. R. Siber. https://doi.org/10.1016/0264-410X(95)00011-O
  8. Biologicals v.18 Comparison of the detoxification courses of histamine-sensitizing, lymphocytosis-promoting and CHO cell-clustering activities in the process of the production of acellular pertussis vaccine. Iwasa, S.;H. Fujiwara. https://doi.org/10.1016/1045-1056(90)90023-S
  9. Acta Pathol. Microbiol. Immun. Scand. v.96 On the effect of Al(OH)₃ as an immunological adjuvant. Jenson, O. M.;C. Koch.
  10. J. Microbiol. Biotechnol. v.10 Phylogenetic analysis of Hepatitis B virus genome isolated from Korean patient serum. Kim, S,-Y.;H.-S. Kang;Y.-S. Kim.
  11. Brit. J. Exp. Path. v.14 The toxoiding of purified diphtheria toxin. Linggood, F. V.;F. S. Muriel;A. J. Fulthorpe;A. J. Woiwod;C. G. Pope.
  12. APMIS v.96 On the effect of Al(OH)₃ as ab immunological adjuvant. Majgaard, J. O.;C. Koch. https://doi.org/10.1111/j.1699-0463.1988.tb05299.x
  13. Vaccine v.12 Relationship between protein adsorptive capacity and the Z-ray diffraction pattern of aluminium hydroxide adjuvants. Masood, H.;J. L. White;S. L. Hem. https://doi.org/10.1016/0264-410X(94)90059-0
  14. J. Microbiol. Biotechnol. v.10 Receptor-mediated endocytosis of Hepatitis B virus preS1 protein in EBY-transformed B-cell line. Park, J.-H.;E.-W. Cho;D. C. Lee;J.-M. Park;Y.-J. Lee;E.-A. Choi;K. L. Kim.
  15. Vaccine v.26 New acellular pertussis containing peadiatric combined vaccines. Pines, E.;M. Barrand;P. Fabre;H. Salomon;C. Blondeau;S. C. Wood;A. Hoffenbach.
  16. Acta Path. Microbiol. Scand. v.65 Irreversible detoxification of purified diphtheria toxin. Scheibel, I.;C. P. Elo.
  17. Biologicals v.27 Non-pertussis components of combination vaccines: Problems with petency testing. Sesardic, D.;C. S. Dawes;K. Mclellan;Z. Durrani;S. E. Yost;M. J. Corbel. https://doi.org/10.1006/biol.1999.0205
  18. Mol. Immunol. v.28 A novel process for preparing an acellulat pertussis vaccine composed of nonpyrogenic toxoids of pertussis toxin and filamentous hemagglutinin. Tan, L. U.;R. E. Fahim;G. Jackson;K. Phillips;P. Wah;D. Alkema;G. Zobrist;A. Herbert;L. Boux;P. Chong. https://doi.org/10.1016/0161-5890(91)90070-Z
  19. CRC Critical Reviews in Immunology v.8 Future prospects for vaccine adjuvants. Warren, H. S.;L. A. Chedid.
  20. J. Microbiol. Biotechnol. v.10 MDP-Lys(L18), a synthetic muramyl dipeptide derivative, enhances antitumor activity of an inactivated tumor vaccine. Yoo, Y. C.;S. Y. Park;K. B. Lee;I. Azuma.